We hypothesized that controlling oxidative stress-induced inflammation by redox modulation and inhibiting hepatic NF-κB activation would assuage NAFLD as well as enhance insulin sensitivity and glucose tolerance. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.